← Human Trials & Peer-Reviewed Studies
[Clinical observation of Qiliqiangxin capsule combined with recombinant human brain natriuretic peptide in patients with acute heart failure]
Plain-language guide to PMID 37032138 (2023): randomized controlled trial study of BNP (Nesiritide) in 240 patients.
Key Facts
- PMID
- 37032138
- Journal
- Zhonghua nei ke za zhi
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Ye M et al. (6 authors)
- DOI
- 10.3760/cma.j.cn112138-20220420-00291
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at BNP (Nesiritide).
Objective: To observe the clinical effect of Qiliqiangxin capsule combined with recombinant human brain natriuretic peptide in acute left heart failure patients 7 days after onset as well as the effects of plasma MDA and ET-1.
Why It Was Studied
Methods: In total, 240 hospitalized patients with acute left heart failure from October 2017 to May 2021 were selected from the Department of Emergency and Critical Care Center of Beijing Anzhen Hospital, Capital Medical University and the Department of Cardiology of the Jilin Provincial People's Hospital.
They were randomly divided into routine treatment group and combined treatment group, with 120 cases in each group.
Who Took Part
The study group was 240 patients.
The routine treatment group was treated with vasodilation, diuresis, cardiotonic and recombinant human brain natriuretic peptide.
The combined treatment group was treated with Qiliqiangxin capsules based on the routine treatment group.
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.
What Was Measured
The measurement data was expressed in x¯±s, the independent sample t-test was used for comparison between groups, and the paired t-test was used for comparison before and after treatment within groups.
The subject headings attached to it are Heart Failure, Natriuretic Peptide, Brain, Stroke Volume, Ventricular Function, Left, Cardiotonic Agents, Drugs, Chinese Herbal and Recombinant Proteins.
What This Means in Plain Language
The paper is a randomized study of BNP (Nesiritide) in 240 patients.
The publication is from 2023 (Zhonghua nei ke za zhi), a journal based in China.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.